ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the second quarter ended June 30, 2024. The company reported record net sales of $95.7 million in the second quarter, an increase of 19 percent year-over-year on a reported basis and 20 percent year-over-year on a constant currency basis. “Our record second quarter results reflect successful global execution of our key strategic plans and growing momentum in our business,” said Thomas Burns, Glaukos chairman and chief executive officer.

“We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases,” Burns said.

Glaukos reported glaucoma record net sales of $75.9 million in Q2 2024, an increase of 23 percent year-over-year. Corneal Health net sales of $19.8 million in Q2 2024 increased 7 percent year-over-year. 

Gross margin for the second quarter of 2024 was approximately 76 percent, the company said, compared with approximately 75 percent in the same period in 2023. Non-GAAP gross margin for the second quarter of 2024 was approximately 82 percent, compared with approximately 82 percent in the same period in 2023.

Loss from operations in the second quarter was $30.0 million, compared with operating loss of $29.1 million in the second quarter of 2023. Non-GAAP loss from operations in the second quarter of 2024 was $23.7 million, compared with a non-GAAP operating loss of $22.8 million in the second quarter of 2023.

Net loss in the second quarter of 2024 was reported at $53.9 million, compared with net loss of $32.8 million in the second quarter of 2023. Non-GAAP net loss in the second quarter of 2024 was $26.3 million, compared with a non-GAAP net loss of $26.6 million in the second quarter of 2023.

The company stated that it ended the second quarter of 2024 with approximately $266.4 million in cash and cash equivalents, short-term investments and restricted cash. It also raised 2024 net sales guidance to a range of $370 million to $376 million, compared with a previous range of $357 million to $365 million.